According to FutureWise analysis the market for triple negative breast cancer is estimated to be US$ 584.3 million in 2022, and is expected to grow at a CAGR of 5.3% over the forecast period of 2023-2031.
Breast cancer that is classified as triple-negative lacks either estrogen or progesterone receptors (ER or PR), as well as making either too little or too much of the HER2 protein. (All three tests yield "negative" results for the cells.) These malignancies tend to affect women under the age of 40 who are Black or carry the BRCA1 mutation more frequently. Triple-negative breast cancer is considered aggressive cancer because it grows quickly and is more likely to have spread when discovered. TNBC is likely to reoccur after treatment than other types of breast cancer. The majority of triple-negative tumours are basal-like molecular subtypes of breast cancer, but the terms are not entirely synonymous. Around 10-15% of all breast tumours are triple-negative breast cancers (TNBC).
HER2 positive/oestrogen receptor (ER) negative subtype and the basal-like subtype are two hormone receptor-negative subtypes of breast cancer that have been identified through gene expression studies. The luminal subtypes, which typically express hormone receptor-related genes, are another major subtype of breast cancer. The prognosis of the subtypes varies, with the two-hormone receptor-negative categories typically having worse results than the luminal divisions. The prognostic environment for breast cancer may alter, though, as a result of advancements in chemotherapy, endocrine therapy, and HER2-targeted therapy. Chemotherapy is the backbone of treatment for triple-negative breast cancer because it is resistant to hormonal treatments like tamoxifen and aromatase inhibitors as well as HER2-targeted medications like trastuzumab. The interest in this group of patients has grown as a result of the absence of targeted medicines.
The market for triple-negative breast cancer is expected to expand due to an increase in breast cancer cases, increased demand for treatment options in private hospitals, increased private healthcare provider investments in healthcare infrastructure, increased medical tourism, and improved healthcare standards and practices. Companies in the global triple-negative breast cancer therapy market are likely to benefit from significant growth opportunities due to rising healthcare spending and demand for better disease diagnosis over the forecast period. Innovation has provided breast cancer patients a great deal of hope for the future because of increased research into novel therapy pathways and strategies to employ existing treatments more successfully alongside or after one another. This is also anticipated to increase demand for the treatment of triple-negative breast cancer. Throughout the projection period, the possibility of unfavourable reactions to breast cancer therapies such as targeted therapy is also anticipated to restrain market expansion. The market for treating triple-negative breast cancer may see new difficulties in the near future as a result of the challenging reimbursement structure and several patent expirations.
FutureWise Market Research has published a report that provides an insightful analysis of triple negative breast cancer market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the triple negative breast cancer market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.